This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo

Rimegepant oral


Oral formulation of rimegepant.

Drugs List

  • rimegepant 75mg oral lyophilisates sugar-free
  • VYDURA 75mg oral lyophilisates sugar-free
  • Therapeutic Indications


    Acute treatment of migraine attacks with or without aura
    Migraine in adults: prophylaxis

    Acute treatment of migraine with or without aura in adults.

    Prevention of episodic migraine in adults who experience 4 or more migraine attacks per month.



    Acute treatment of migraine
    75mg once daily, as needed.

    Prevention of migraine
    75mg every other day. Maximum daily dose is 75mg.

    Additional Dosage Information

    Avoid a second/additional dose of rimegepant within 48 hours of moderate CYP3A4 inhibitors and strong P-gp inhibitors. Avoid taking rimegepant within 2 weeks of discontinuing CYP3A4 inducers.


    Children under 18 years
    Renal impairment - creatinine clearance below 15ml/minute
    Severe hepatic impairment - Child-Pugh score greater than or equal to 10

    Precautions and Warnings

    Severe renal impairment

    Avoid second dose within 48 hours of moderate CYP3A4/strong P-gp inhibitors
    Discontinue if hypersensitivity reactions occur
    Advise patient not to take St John's wort concurrently
    Advise patient to avoid grapefruit products

    In the event of frequent or daily headaches, medication overuse headache should be suspected and treatment should be discontinued.

    Pregnancy and Lactation


    Rimegepant is contraindicated during pregnancy.

    Use of rimegepant during pregnancy is contraindicated by the manufacturer. At the time of writing, there is limited published information regarding the use of rimegepant during pregnancy. Potential risks are unknown.


    Use rimegepant with caution during breastfeeding.

    The manufacturer advises caution if rimegepant is used when breastfeeding. Whilst available data indicates rimegepant is present in human breast milk, the quantity is not considered to be sufficient to cause adverse effects in the breastfed infant. Effects on exposed infants are unknown.

    Side Effects

    Hypersensitivity reactions


    It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.

    The following number will direct the caller to the relevant local centre (0844) 892 0111

    Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( ) or if this is unavailable at the backup site ( ).

    Further Information

    Last Full Review Date: September 2022

    Reference Sources

    Summary of Product Characteristics: Vydura 75mg oral lyophilisate. Pfizer Ltd. Revised July 2022.

    Access the full UK drug database with a FREE Medscape UK Account
    It takes just a few minutes, and you’ll get unlimited access to information on over 11,000 UK drugs.
    Register for Free

    Already a member? Log in

    Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content

    FDB Logo

    FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.